Curcumin derivatives as new ligands of Aβ peptides

Journal of Biotechnology

Volumn 156, Issue 4, 2011, Pages 317-324

  Airoldi, Cristina ^a   Zona, Cristiano ^a   Sironi, Erika ^a   Colombo, Laura ^b   Messa, Massimo ^b   Aurilia, Dario ^a   Gregori, Maria ^a   Masserini, Massimo ^a   Salmona, Mario ^b   Nicotra, Francesco ^a   La Ferla, Barbara ^a  

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

^b MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

Alzheimer's disease; A ligands; A peptides; Brain amyloid plaque staining; Conformational analysis; Curcumin derivatives; NMR interaction studies

Indexed keywords

CHEMICAL STABILITY; NEURODEGENERATIVE DISEASES; PEPTIDES; PROTEINS;

ALZHEIMER'S DISEASE; AMYLOID PLAQUES; CONFORMATIONAL ANALYSIS; CURCUMIN DERIVATIVES; INTERACTION STUDIES;

LIGANDS;

2 [3,5 BIS(4 HYDROXY 3 METHOXYSTYRYL) 1H PYRAZOL 1 YL] N (PROP 2 YN 1 YL)ACETAMIDE; 2 [3,5 BIS(4 HYDROXY 3 METHOXYSTYRYL) 1H PYRAZOL 1 YL] N [2 [2 (2 HYDROXYETHOXY)ETHOXY[ETHYL] ACETAMIDE; 2 [3,5 BIS(4 HYDROXY 3 METHOXYSTYRYL) 1H PYRAZOL 1 YL] N [[1 [2 [2 (2 YDROXYETHOXY)ETHOXY]ETHYL] 1H 1,2,3 TRIAZOL 4 YL]METHYL]ACETAMIDE; 2 [3,5 BIS(4 HYDROXY 3 METHOXYSTYRYL) 1H PYRAZOL 1 YL]ACETIC ACID; 4,4' [[1 (2 HYDROXYETHYL) 1H PYRAZOLE 3,5 DIYL]BIS(ETHENE 2,1 DIYL]BIS(2 METHOXYPHENOL); AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; CURCUMIN; CURCUMIN DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; CARBON NUCLEAR MAGNETIC RESONANCE; DRUG PROTEIN BINDING; DRUG SOLUBILITY; DRUG SYNTHESIS; MOLECULAR DYNAMICS; MOLECULAR MECHANICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTON NUCLEAR MAGNETIC RESONANCE;

EID: 82955162689     PISSN: 01681656     EISSN: 18734863     Source Type: Journal    
DOI: 10.1016/j.jbiotec.2011.07.021     Document Type: Article

References (39)

1. Airoldi C., Colombo L., Manzoni C., Sironi E., Natalello A., Doglia S.M., Forloni G., Tagliavini F., Del Favero E., Cantu L., Nicotra F., Salmona M. Tetracycline prevents Aβ oligomer toxicity through an atypical supramolecular interaction. Organic & Biomolecular Chemistry 2011, 9:463-472.
2. Allinger N.L., Yuh Y.H., Lii J.H. Molecular mechanics - the MM3 force-field for hydrocarbons. 1. Journal of the American Chemical Society 1989, 111:8551-8566.
3. Bernabe-Pineda M., Ramirez-Silva M.T., Romero-Romo M., Gonzadlez-Vergara E., Rojas-Hernandez A. Determination of acidity constants of curcumin in aqueous solution and apparent rate constant of its decomposition. Spectrochimica Acta Part A-Molecular and Biomolecular Spectroscopy 2004, 60:1091-1097.
4. Berteau O., Sandstrom C., Bielicki J., Anson D.S., Kenne L. Glycosidase-substrate interactions analysis by STD-NMR spectroscopy: study of alpha-l-fucosidase. Journal of the American Chemical Society 2003, 125:15296-15297.
5. Biet T., Peters T. Molecular recognition of UDP-Gal by beta-1,4-galactosyltransferase T1. Angewandte Chemie - International Edition 2001, 40:4189-4192.
6. Brookmeyer R., Gray S., Kawas C. Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. American Journal of Public Health 1998, 88:1337-1342.
7. Brookmeyer R., Corrada M.M., Curriero F.C., Kawas C. Survival following a diagnosis of Alzheimer disease. Archives of Neurology 2002, 59:1764-1767.
8. Bush A.I. Metal complexing agents as therapies for Alzheimer's disease. Neurobiology of Aging 2002, 23:1031-1038.
9. Cardoso I., Merlini G., Saraiva M.J. 4'-iodo-4'-Deoxydoxorubicin and tetracyclines disrupt transthyretin amyloid fibrils in vitro producing noncytotoxic species: screening for TTR fibril disrupters. Faseb Journal 2003, 17:803-809.
10. Chishti M.A., Yang D.S., Janus C., Phinney A.L., Horne P., Pearson J., Strome R., Zuker N., Loukides J., French J., Turner S., Lozza G., Grilli M., Kunicki S., Morissette C., Paquette J., Gervais F., Bergeron C., Fraser P.E., Carlson G.A., St George-Hyslop P., Westaway D. Early-onset amyloid deposition and cognitive deficits in transgenic mice expressing a double mutant form of amyloid precursor protein 695. Journal of Biological Chemistry 2001, 276:21562-21570.
11. Di Fede G., Catania M., Morbin M., Rossi G., Suardi S., Mazzoleni G., Merlin M., Giovagnoli A.R., Prioni S., Erbetta A., Falcone C., Gobbi M., Colombo L., Bastone A., Beeg M., Manzoni C., Francescucci B., Spagnoli A., Cantu L., Del Favero E., Levy E., Salmona M., Tagliavini F. A recessive mutation in the APP gene with dominant-negative effect on amyloidogenesis. Science 2009, 323:1473-1477.
12. Giaccone G., Morbin M., Moda F., Botta M., Mazzoleni G., Uggetti A., Catania M., Moro M.L., Redaelli V., Spagnoli A., Rossi R.S., Salmona M., Di Fede G., Tagliavini F. Neuropathology of the recessive A673V APP mutation: Alzheimer disease with distinctive features. Acta Neuropathologica 2010, 120:803-812.
13. Goel A., Kunnumakkara A.B., Aggarwal B.B. Curcumin as " Curecumin" : from kitchen to clinic. Biochemical Pharmacology 2008, 75:787-809.
14. Kaewnopparat N., Kaewnopparat S., Jangwang A., Maneenaun D., Chuchome T., Panichayapakaranant P. Increased solubility, dissolution and physicochemical studies of Curcumin-polyvinylpyrrolidone K-30 solid dispersions. World Academy of Science, Engineering and Technology 2009, 55:229-234.
15. Kelloff G.J., Crowell J.A., Hawk E.T., Steele V.E., Lubet R.A., Boone C.W., Covey J.M., Doody L.A., Omenn G.S., Greenwald P., Hong W.K., Parkinson D.R., Bagheri D., Baxter G.T., Blunden M., Doeltz M.K., Eisenhauer K.M., Johnson K., Knapp G.G., Longfellow D.G., Malone W.F., Nayfield S.G., Seifried H.E., Swall L.M., Sigman C.C. Strategy and planning for chemopreventive drug development: Clinical Development Plans II. Journal of Cellular Biochemistry 1996, 54-71.
16. Koronyo-Hamaoui M., Koronyo Y., Ljubimov A.V., Miller C.A., Ko M.K., Black K.L., Schwartz M., Farkas D.L. Identification of amyloid plaques in retinas from Alzheimer's patients and noninvasive in vivo optical imaging of retinal plaques in a mouse model. NeuroImage 2011, 54:S204-S217.
17. Lim G.P., Chu T., Yang F.S., Beech W., Frautschy S.A., Cole G.M. The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse. Journal of Neuroscience 2001, 21:8370-8377.
18. MacroModel, 2008, 9.6 ed. Schrödinger, LLC, New York.
19. Maestro, 2010, 9.1 ed. Schrödinger, LLC, New York.
20. Masters C.L., Cappai R., Barnham K.J., Villemagne V.L. Molecular mechanisms for Alzheimer's disease: implications for neuroimaging and therapeutics. Journal of Neurochemistry 2006, 97:1700-1725.
21. Meyer B., Peters T. NMR spectroscopy techniques for screening and identifying ligand binding to protein receptors. Angewandte Chemie - International Edition 2003, 42:864-890.
22. Narlawar R., Pickhardt M., Leuchtenberger S., Baumann K., Krause S., Dyrks T., Weggen S., Mandelkow E., Schmidt B. Curcumin-derived pyrazoles and isoxazoles: Swiss army knives or blunt tools' for Alzheimer's disease?. Chemmedchem 2008, 3:165-172.
23. Pollack S.J., Sadler I.I.J., Hawtin S.R., Tailor V.J., Shearman M.S. Sulfonated dyes attenuate the toxic effects of β-amyloid in a structure-specific fashion. Neuroscience Letters 1995, 197:211-214.
24. Re F., Airoldi C., Zona C., Masserini M., La Ferla B., Quattrocchi N., Nicotra F. β-amyloid aggregation inhibitors: small molecules as candidate drugs for therapy of Alzheimer's disease. Current Medicinal Chemistry 2010, 17:2990-3006.
25. Reinke A.A., Gestwicki J.E. Structure-activity relationships of amyloid β-aggregation inhibitors based on curcumin: influence of linker length and flexibility. Chemical Biology and Drug Design 2007, 70:206-215.
26. Sabate R., Estelrich J. Stimulatory and inhibitory effects of alkyl bromide surfactants on β-amyloid fibrillogenesis. Langmuir 2005, 21:6944-6949.
27. Salmona M., Morbin M., Massignan T., Colombo L., Mazzoleni G., Capobianco R., Diomede L., Thaler F., Mollica L., Musco G., Kourie J.J., Bugiani O., Sharma D., Inouye H., Kirschner D.A., Forloni G., Tagliavini F. Structural properties of Gerstmann-Straussler-Scheinker disease amyloid protein. Journal of Biological Chemistry 2003, 278:48146-48153.
28. Sato H., Hayashi E., Yamada N., Yatagai M., Takahara Y. Further studies on the site-specific protein modification by microbial transglutaminase. Bioconjugate Chemistry 2001, 12:701-710.
29. Schneekloth A.R., Pucheault M., Tae H.S., Crews C.M. Targeted intracellular protein degradation induced by a small molecule: en route to chemical proteomics. Bioorganic & Medicinal Chemistry Letters 2008, 18:5904-5908.
30. Selkoe D.J. Clearing the brain's amyloid cobwebs. Neuron 2001, 32:177-180.
31. Sisodia S.S., St George-Hyslop P.H. Gamma-secretase, notch, A beta and Alzheimer's disease: where do the presenilins fit in?. Nature Reviews Neuroscience 2002, 3:281-290.
32. Still W.C., Tempczyk A., Hawley R.C., Hendrickson T. Semianalutical treatment of solvation for molecular mechanics and dynamics. Journal of the American Chemical Society 1990, 112:6127-6129.
33. Taniguchi S., Suzuki N., Masuda M., Hisanaga S., Iwatsubo T., Goedert M., Hasegawa M. Inhibition of heparin-induced tau filament formation by phenothiazines, polyphenols, and porphyrins. Journal of Biological Chemistry 2005, 280:7614-7623.
34. Thoma K., Rombach R., Ullmann E. Thin-layer chromatographic differentiation of homologous polyethileneglycols. Scientia Pharmaceutica 1964, 32:216-224.
35. Thomas T., Nadackal T.G., Thomas K. Aspirin and non-steroidal anti-inflammatory drugs inhibit amyloid-β aggregation. Neuroreport 2001, 12:3263-3267.
36. Tonnesen H.H., Karlsen J. Studies on Curcumin and curcuminoids. 6. Kinetics of curcumin degradation in aqueous-solution. Zeitschrift Fur Lebensmittel-Untersuchung Und-Forschung 1985, 180:402-404.
37. Wang Y.J., Pan M.H., Cheng A.L., Lin L.I., Ho Y.S., Hsieh C.Y., Lin J.K. Stability of Curcumin in buffer solutions and characterization of its degradation products. Journal of Pharmaceutical and Biomedical Analysis 1997, 15:1867-1876.
38. Yanagisawa D., Shirai N., Amatsubo T., Taguchi H., Hirao K., Urushitani M., Morikawa S., Inubushi T., Kato M., Kato F., Morino K., Kimura H., Nakano I., Yoshida C., Okada T., Sano M., Wada Y., Wada K., Yamamoto A., Tooyama I. Relationship between the tautomeric structures of Curcumin derivatives and their A β-binding activities in the context of therapies for Alzheimer's disease. Biomaterials 2010, 31:4179-4185.
39. Zhao B.L., Li X.J., He R.G., Cheng S.J., Xin W.J. Scavenging effect of extracts of green tea and natural antioxidants on active oxygen radicals. Cell Biophysics 1989, 14:175-185.